/
RNAZ
$5.24+$0.27 (+5.43%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$4.7M
1M shares
52-week range
$3.82 – $20.99
8% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
14.20%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-3910362.76
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $42.5K | $98.6K | $516.7K | $534.9K | $0 |
| Gross profit | $0 | $0 | $0 | −$42.5K | −$98.6K | −$516.7K | −$534.9K | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $82.5K | $226.3K | $284.5K | $2.8M | $10.2M | $12.3M | $9.6M | $13.4M |
| Operating income | −$384.0K | −$456.9K | −$726.6K | −$6.2M | −$18.7M | −$19.4M | −$15.7M | −$28.0M |
| EBITDA | −$69.4K | −$450.2K | −$1.9M | −$6.7M | −$17.5M | −$18.0M | −$16.2M | −$34.3M |
| Net income | −$453.4K | −$607.2K | −$2.3M | −$6.8M | −$17.6M | −$18.5M | −$16.8M | −$34.7M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -2359.09 | -72.00 | -293.76 | -648.00 | -1080.00 | -3453.53 | -47.14 | -52.59 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $500000 | $-8.96 | $-8.96–$-8.96 | 1 |
| 2027 | $10M | $-6.72 | $-6.72–$-6.72 | 1 |
| 2028 | $10M | $-5.60 | $-5.60–$-5.60 | 1 |
| 2029 | $28M | $-5.04 | $-5.04–$-5.04 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$30.10
Price
$5.24
Implied upside
+475%
Peer comparison
TransCode Therapeutics, Inc. Common Stock
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
www.transcodetherapeutics.com- Employees
- 12
- IPO / List date
- Jul 9, 2021
- HQ
- BOSTON, MA
Held by traders on TradeandTell
No one on the platform currently holds RNAZ.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in RNAZ as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-05-15 | 1-for-28reverse |
| 2024-12-04 | 1-for-33reverse |
| 2024-01-16 | 1-for-40reverse |
| 2023-05-23 | 1-for-20reverse |
Recent trades on TradeandTell
No one on the platform has traded RNAZ yet.
